These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 26508666

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, Pilote L.
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G, Bhave PD, Girotra S, Hodgson-Zingman D, Mazur A, Giudici M, Chrischilles E, Vaughan Sarrazin MS.
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S.
    Thromb Haemost; 2015 Nov 25; 114(6):1277-89. PubMed ID: 26446507
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.
    Circulation; 2015 Sep 29; 132(13):1252-60. PubMed ID: 26199338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
    Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ.
    Ann Intern Med; 2017 Dec 19; 167(12):845-854. PubMed ID: 29132153
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G.
    J Am Heart Assoc; 2015 Apr 10; 4(4):. PubMed ID: 25862791
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.
    Circulation; 2015 Jan 13; 131(2):157-64. PubMed ID: 25359164
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J, Wijtvliet EP, Veeger NJ, Geluk CA, Bartels GL, Posma JL, Piersma-Wichers M, Van Gelder IC, Rienstra M, Tieleman RG.
    Europace; 2016 Sep 13; 18(9):1319-27. PubMed ID: 26843571
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT.
    Stroke; 2016 Feb 13; 47(2):441-9. PubMed ID: 26732563
    [Abstract] [Full Text] [Related]

  • 16. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.
    J Am Coll Cardiol; 2013 Sep 03; 62(10):900-8. PubMed ID: 23770182
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J, Delaitre O, Hammès F, de Pouvourville G.
    Arch Cardiovasc Dis; 2014 Sep 03; 107(6-7):381-90. PubMed ID: 24973113
    [Abstract] [Full Text] [Related]

  • 18. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, Park HJ, Kim Y, Cho JY, Kim MC, Sim DS, Yoon HJ, Yoon NS, Kim KH, Hong YJ, Kim JH, Ahn Y, Jeong MH, Park JC, Cho JG.
    Europace; 2017 Dec 01; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [Abstract] [Full Text] [Related]

  • 19. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY.
    Am J Med; 2014 Dec 01; 127(12):1172-8.e5. PubMed ID: 25193361
    [Abstract] [Full Text] [Related]

  • 20. Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care.
    Schneeweiss S, Gopalakrishnan C, Bartels DB, Franklin JM, Zint K, Kulldorff M, Huybrechts KF.
    Circ Cardiovasc Qual Outcomes; 2019 Feb 01; 12(2):e005173. PubMed ID: 30764655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.